Background: Rates of malignancies and hospitalized infectious events (HIEs) among psoriasis patients are higher than the general population, but it is unclear if higher rates are associated with the underlying inflammatory state, treatments, or both.
Objectives: To assess the incidence of malignancies and HIEs in a healthy US population, a psoriasis population, and four treated psoriasis populations.
Methods: Using a US claims database, we identified a general population, a psoriasis cohort, and four treatment cohorts (non-biologic systemics, etanercept, other TNF blockers (adalimumab, infliximab), and phototherapy) to assess incidence of lymphomas, non-melanoma skin cancer (NMSC), all malignancies (excl. NMSC), and HIEs, standardized for age and sex.
Results: Among 40,987 psoriasis patients, 11% were prescribed non-biologics, 15% etanercept, 6% other TNF blockers, and 11% phototherapy. For all cancers, the psoriasis population rate (114/10,000 person-years) was 20% greater than the rate found in the general population (95/10,000 person-years). For NMSC, the psoriasis population rate (129/10,000 person-years) was 65% greater than the general population rate (78/10,000 person-years). The incidence rate for each treatment modality was lower than the overall psoriasis cohort, except for phototherapy. There was little difference in the rates of lymphomas. NMSC rates were higher among phototherapy patients. HIE rates ranged from 165/10,000 person-years for the phototherapy group to 262/10,000 person-years for the other anti-TNF group.
Conclusions: Psoriasis patients appear to have higher rates of malignancy and HIE than the general population, with little difference in rates between the treatment methods, except for a higher rate of cancer among those receiving phototherapy.
